Media Gallery
In the News
The Fight against HIV- Cabotegravir
Webinars
Sub-Saharan Congenital Abnomalies Network
Docu-series
Impact of COVID-19 Lockdown
Press Stories
Broadcast Media
Press Stories
Print media
UGANDA | GLOBAL PRESS JOURNAL | NAKISANZE SEGAWA| DECEMBER 2022Drug Could Beat Back HIV — If People Could Get It
Cabotegravir is a promising HIV prevention medication that’s approved in countries like the United States. But in sub-Saharan Africa, access encounters a number of hurdles.
KAMPALA, UGANDA | DAILY MONITOR | TONNY ABET | AUGUST 2022Number of HIV-free babies increases - study
Prof. Philippa Musoke, the Executive Director for Makerere University - Johns Hopkins University Research Collaboration (MU-JHU), said the transmission rates among mothers getting antenatal care at Mulago and Kawempe hospitals have declined from 25 percent in 2010 to 2 percent.
KAMPALA, UGANDA | SCIE-NEWS | ESTHER NAKKAZI | JANUARY 2020Uganda to participate in long-acting injectable HIV prevention option study
Uganda will participate in a clinical trial that will evaluate the safety and efficacy of a six months long-lasting injectable, Lenacapavir (LEN), and an oral daily pill, Descovy (F/TAF) as pre-exposure prophylaxis (PrEP) products.
KAMPALA, UGANDA | THE INDEPENDENT | MARCH 2020Health workers challenged on detecting TB among children
KAMPALA, UGANDA | THE INDEPENDENT | FLAVIA NASSAKA | FEBRUARY 2019HIV and young girls
KAMPALA, UGANDA | THE INDEPENDENT | JUNE 2019Popular birth control shot does not increase HIV risk – Study
KAMPALA, UGANDA | THE INDEPENDENT | JANUARY 2017Ugandan lab recognized for best practice in lab medicine
KAMPALA, UGANDA | THE NEW VISION | HILARY BAINEMIGISHA | JANUARY 2016Vaginal ring cuts HIV risk by nearly one-third: studies
© 2022 MU-JHU Research Collaboration. All rights reserved